228 related articles for article (PubMed ID: 37404831)
21. CD169
Nagata M; Ishizaka K; Asano T
Res Rep Urol; 2023; 15():1-7. PubMed ID: 36660299
[TBL] [Abstract][Full Text] [Related]
22. Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses.
Komohara Y; Ohnishi K; Takeya M
Cancer Sci; 2017 Mar; 108(3):290-295. PubMed ID: 28002629
[TBL] [Abstract][Full Text] [Related]
23. CD169-positive macrophages enhance abscopal effect of radiofrequency ablation therapy in liver cancer.
Song X; Li N; Liu Y; Wang Z; Wang T; Tan S; Li C; Qiu C; Gao L; Asano K; Tanaka M; Liang X; Liu X; Ma C
Transl Oncol; 2022 Jan; 15(1):101306. PubMed ID: 34883446
[TBL] [Abstract][Full Text] [Related]
24. CD169 identifies an anti-tumour macrophage subpopulation in human hepatocellular carcinoma.
Zhang Y; Li JQ; Jiang ZZ; Li L; Wu Y; Zheng L
J Pathol; 2016 Jun; 239(2):231-41. PubMed ID: 27174787
[TBL] [Abstract][Full Text] [Related]
25. High CD169 expression in lymph node macrophages predicts a favorable clinical course in patients with esophageal cancer.
Takeya H; Shiota T; Yagi T; Ohnishi K; Baba Y; Miyasato Y; Kiyozumi Y; Yoshida N; Takeya M; Baba H; Komohara Y
Pathol Int; 2018 Dec; 68(12):685-693. PubMed ID: 30516869
[TBL] [Abstract][Full Text] [Related]
26. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation.
Kawasaki N; Vela JL; Nycholat CM; Rademacher C; Khurana A; van Rooijen N; Crocker PR; Kronenberg M; Paulson JC
Proc Natl Acad Sci U S A; 2013 May; 110(19):7826-31. PubMed ID: 23610394
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma.
Saito Y; Ohnishi K; Miyashita A; Nakahara S; Fujiwara Y; Horlad H; Motoshima T; Fukushima S; Jinnin M; Ihn H; Takeya M; Komohara Y
Cancer Immunol Res; 2015 Dec; 3(12):1356-63. PubMed ID: 26297710
[TBL] [Abstract][Full Text] [Related]
28. Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes.
Komohara Y; Kurotaki D; Tsukamoto H; Miyasato Y; Yano H; Pan C; Yamamoto Y; Fujiwara Y
Cancer Sci; 2023 Jun; 114(6):2220-2229. PubMed ID: 36748310
[TBL] [Abstract][Full Text] [Related]
29. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer.
Yonemitsu K; Pan C; Fujiwara Y; Miyasato Y; Shiota T; Yano H; Hosaka S; Tamada K; Yamamoto Y; Komohara Y
Sci Rep; 2022 Jul; 12(1):12007. PubMed ID: 35835809
[TBL] [Abstract][Full Text] [Related]
30. Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Qiu SQ; Waaijer SJH; Zwager MC; de Vries EGE; van der Vegt B; Schröder CP
Cancer Treat Rev; 2018 Nov; 70():178-189. PubMed ID: 30227299
[TBL] [Abstract][Full Text] [Related]
31. Elevated CD169 expressing monocyte/macrophage promotes systemic inflammation and disease progression in cirrhosis.
Xu L; Huang C; Zheng X; Gao H; Zhang S; Zhu M; Dai X; Wang G; Wang J; Chen H; Zhu H; Chen Z
Clin Exp Med; 2024 Feb; 24(1):45. PubMed ID: 38413535
[TBL] [Abstract][Full Text] [Related]
32. CD169 Defines Activated CD14
Affandi AJ; Olesek K; Grabowska J; Nijen Twilhaar MK; Rodríguez E; Saris A; Zwart ES; Nossent EJ; Kalay H; de Kok M; Kazemier G; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Garcia-Vallejo JJ; Storm G; van Kooyk Y; den Haan JMM
Front Immunol; 2021; 12():697840. PubMed ID: 34394090
[TBL] [Abstract][Full Text] [Related]
33. Tumor Properties Mediate the Relationship between Peripheral Blood Monocytes and Tumor-Associated Macrophages in Breast Cancer.
Stakheyeva M; Patysheva M; Kaigorodova E; Zavyalova M; Tarabanovskaya N; Choynzonov E; Cherdyntseva N
Cancer Invest; 2022 May; 40(5):442-456. PubMed ID: 34882039
[TBL] [Abstract][Full Text] [Related]
34. Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon.
Akiyama H; Ramirez NP; Gibson G; Kline C; Watkins S; Ambrose Z; Gummuluru S
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794041
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma.
van Dinther D; Veninga H; Revet M; Hoogterp L; Olesek K; Grabowska J; Borg EGF; Kalay H; van Kooyk Y; den Haan JMM
Front Immunol; 2018; 9():1997. PubMed ID: 30237798
[TBL] [Abstract][Full Text] [Related]
36. Human breast cancer cells educate macrophages toward the M2 activation status.
Sousa S; Brion R; Lintunen M; Kronqvist P; Sandholm J; Mönkkönen J; Kellokumpu-Lehtinen PL; Lauttia S; Tynninen O; Joensuu H; Heymann D; Määttä JA
Breast Cancer Res; 2015 Aug; 17(1):101. PubMed ID: 26243145
[TBL] [Abstract][Full Text] [Related]
37. Reduced number of CD169
Strömvall K; Sundkvist K; Ljungberg B; Halin Bergström S; Bergh A
Prostate; 2017 Nov; 77(15):1468-1477. PubMed ID: 28880401
[TBL] [Abstract][Full Text] [Related]
38. Functions of CD169 positive macrophages in human diseases (Review).
Liu Y; Xia Y; Qiu CH
Biomed Rep; 2021 Feb; 14(2):26. PubMed ID: 33408860
[TBL] [Abstract][Full Text] [Related]
39. A Higher Frequency of CD14+ CD169+ Monocytes/Macrophages in Patients with Colorectal Cancer.
Li C; Luo X; Lin Y; Tang X; Ling L; Wang L; Jiang Y
PLoS One; 2015; 10(10):e0141817. PubMed ID: 26509874
[TBL] [Abstract][Full Text] [Related]
40. The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study.
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
BMC Cancer; 2017 Jun; 17(1):404. PubMed ID: 28583114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
